GMED Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 12.62% compared to Globus Medical's net margin of 14.45%. Globus Medical's return on equity of 4.59% beat Boston Scientific's return on equity of 9.57%.

Globus Medical has a consensus price target of $85.17, signalling upside risk potential of 44.45%. On the other hand Boston Scientific has an analysts' consensus of $116.96 which suggests that it could grow by 11.93%. Given that Globus Medical has higher upside potential than Boston Scientific, analysts believe Globus Medical is more attractive than Boston Scientific.

Globus Medical has a beta of 1.324, which suggesting that the stock is 32.371% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $598.1M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Globus Medical's net income of $75.5M is lower than Boston Scientific's net income of $674M. Notably, Globus Medical's price-to-earnings ratio is 44.00x while Boston Scientific's PE ratio is 76.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.26x versus 8.86x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Enovis has a net margin of 12.62% compared to Globus Medical's net margin of -10.02%. Globus Medical's return on equity of 4.59% beat Enovis's return on equity of -26.77%.

Globus Medical has a consensus price target of $85.17, signalling upside risk potential of 44.45%. On the other hand Enovis has an analysts' consensus of $56.50 which suggests that it could grow by 79.02%. Given that Enovis has higher upside potential than Globus Medical, analysts believe Enovis is more attractive than Globus Medical.

Globus Medical has a beta of 1.324, which suggesting that the stock is 32.371% more volatile than S&P 500. In comparison Enovis has a beta of 1.583, suggesting its more volatile than the S&P 500 by 58.325%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Enovis pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $598.1M, which are larger than Enovis quarterly revenues of $558.8M. Globus Medical's net income of $75.5M is higher than Enovis's net income of -$56M. Notably, Globus Medical's price-to-earnings ratio is 44.00x while Enovis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.26x versus 0.82x for Enovis. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of 12.62% compared to Globus Medical's net margin of -5.14%. Globus Medical's return on equity of 4.59% beat Integer Holdings's return on equity of 4.85%.

Globus Medical has a consensus price target of $85.17, signalling upside risk potential of 44.45%. On the other hand Integer Holdings has an analysts' consensus of $148.75 which suggests that it could grow by 25.73%. Given that Globus Medical has higher upside potential than Integer Holdings, analysts believe Globus Medical is more attractive than Integer Holdings.

Globus Medical has a beta of 1.324, which suggesting that the stock is 32.371% more volatile than S&P 500. In comparison Integer Holdings has a beta of 1.030, suggesting its more volatile than the S&P 500 by 3.045%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $598.1M, which are larger than Integer Holdings quarterly revenues of $437.4M. Globus Medical's net income of $75.5M is higher than Integer Holdings's net income of -$22.5M. Notably, Globus Medical's price-to-earnings ratio is 44.00x while Integer Holdings's PE ratio is 56.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.26x versus 2.39x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 12.62% compared to Globus Medical's net margin of 6.22%. Globus Medical's return on equity of 4.59% beat Insulet's return on equity of 36.9%.

Globus Medical has a consensus price target of $85.17, signalling upside risk potential of 44.45%. On the other hand Insulet has an analysts' consensus of $328.73 which suggests that it could grow by 2.29%. Given that Globus Medical has higher upside potential than Insulet, analysts believe Globus Medical is more attractive than Insulet.

Globus Medical has a beta of 1.324, which suggesting that the stock is 32.371% more volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $598.1M, which are larger than Insulet quarterly revenues of $569M. Globus Medical's net income of $75.5M is higher than Insulet's net income of $35.4M. Notably, Globus Medical's price-to-earnings ratio is 44.00x while Insulet's PE ratio is 57.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 3.26x versus 10.81x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.